Table 1 HLA class I restricted peptides used for IFN-γ ELISpot assays

g1

p17 (71–79)

GSEELRSLY

A1

g2

p17 (77–85)

SLYNTVATL

A*0201

g3

p17 (20–28)

RLRPGGKKK

A3

g4

p24 (217–227)

ACQGVGGPGHK

A11

g5

p17 (84–92)

TLYCVHQRI

A11

g6

p17 (28–36)

KYKLKHIVW

A24

g7

p24 (35–43)

EVIPMFSAL

A26

g8

p24 (16–23)

SPRTLNAW

B7

g9

p17 (74–82)

ELRSLYNTV

B8

g10

p24 (197–205)

DCKTILKAL

B8

g11

p17 (93–101)

EIKDTKEAL

B8

g12

p17 (24–31)

GGKKKKYKL

B8

g13

p24 (131–140)

KRWIILGLNK

B27

g14

p17 (36–44)

WASRELERF

B35^A

g15

p17 (124–132)

NSSKVSQNY

B35^A

g16

p24 (122–130)

PPIPVGDIY

B35^A

g17

p24 (174–184)

AEQASQDVKNW

B44

g18

p24 (83–92)

VHPVHAGPIA

B55

g19

p24 (108–117)

TSTLQEQIGW

B57^B

g20

p24 (176–184)

QASQEVKNW

B57^B

g21

p24 (15–23)

ISPRTLNAW

B57^B

g22

p24 (32–40)

FSPEVIPMF

B57^B

g23

p17 (92–101)

IEIKDTKEAL

B61

Pol

p1

RT (309–317)

ILKEPVHGV

A*0201

p2

RT (179–187)

VIYQYMDDL

A2

p3

RT (485–493)

ALQDSGLEV

A2

p4

RT (341–350)

IYQEPFKLNK

A11

p5

RT (158–166)

AIFQSSMTK

A11

p6

IN (179–188)

AVFIHNFKRK

A11

p7

RT (448–457)

RETKLGKAGY

A29

p8

RT (392–401)

PIQKETWETW

A32

p9

RT (18–26)

GPKVKQWPL

B8

p10

RT (175–183)

HPDIVIYQY

B35^A

p11

RT (156–164)

SPAIFQSSM

B35^A

p12

RT (432–441)

EPIVGAETFY

B35^A

p13

RT (203–212)

EELRQHLLRW

B44

p14

RT (397–406)

TWETWWTEYW

B44

Nef

n1

nef (180–189)

VLEWRFDSRL

A2

n2

nef (73–82)

QVPLRPMTYK

A11

n3

nef (75–82)

PLRPMTYK

A11

n4

nef (84–92)

AVDLSHFLK

A11

n5

nef (128–137)

TPGPGVRYPL

B7

n6

nef (90–97)

FLKEKGGL

B8

n7

nef (13–20)

WPTVRERM

B8

n8

nef (135–143)

YPLTFGWCY

B18/B49

n10

nef (186–193)

DSRLAFHH

B35^A

n11

nef (74–84)

VPLRPMTY

B35^A

n12

nef (116–125)

HTQGYFPDWQ

B57^B

n13

nef (92–100)

KEKGGLEGL

B61